NCT02856828 is a NA clinical trial of DIE in Radiation Exposure, sponsored by Duke University.

Who is sponsoring NCT02856828?

NCT02856828 is sponsored by Duke University.

What drugs are being tested in NCT02856828?

Interventions in NCT02856828: DIE.

What condition does NCT02856828 study?

NCT02856828 studies Radiation Exposure.

Is NCT02856828 still recruiting?

NCT02856828 is currently terminated. Last updated 15 October 2019.

Are results published for NCT02856828?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-15 · How we verify

NCT02856828

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Use of an Enhanced Fluoroscopic Imaging Device to Reduce Radiation Exposure and Operative Time During Intramedullary Nailing of Hip Fractures

Terminated NA Results posted Last updated 15 October 2019

What this trial tests

NA trial testing DIE in Radiation Exposure in 5 participants. Terminated before completion.

Timeline

1 March 2017

Primary endpoint
6 February 2018

6 February 2018

Quick facts

Lead sponsor	Duke University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	5
Start date	1 March 2017
Primary completion	6 February 2018
Estimated completion	6 February 2018
Sites	1 location across United States

Drugs / interventions tested

Conditions studied

Radiation Exposure — all drugs for Radiation Exposure →

Sponsor

Duke University

Who can join

18 and older, any sex, with Radiation Exposure. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Radiation Exposure to Patient During Intramedullary Nail Placement for Treatment of Hip Fractures as Measured by Dosimeter Badge Primary · intraoperatively

Participant 1

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	5.12
Control Group	NA

Participant 2

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	12.9

Participant 3

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	9.79
Control Group	NA

Participant 4

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	7.93

Participant 5

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	15.41

Radiation Exposure to Surgeon During Intramedullary Nail Placement for Treatment of Hip Fractures as Measured by Dosimeter Badge Primary · intraoperatively

Primary Surgeon 1

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	0.7
Control Group	NA

Primary Surgeon 2

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	1.9

Primary Surgeon 3

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	1.6
Control Group	NA

Primary Surgeon 4

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	1.2

Primary Surgeon 5

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	3.1

Radiation Exposure to Scrub Tech During Intramedullary Nail Placement for Treatment of Hip Fractures as Measured by Dosimeter Badge Primary · intraoperatively

Surgical Technician 1

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	0.5
Control Group	NA

Surgical Technician 2

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	1.1

Surgical Technician 3

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	0.9
Control Group	NA

Surgical Technician 4

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	0.9

Surgical Technician 5

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	0.1

Image Quality and Reproducibility of Desired Images Secondary · intraoperatively

Measured by questionnaire related to image quality. Quality scale of 1-10, 1 being poor image quality and 10 being excellent image quality.

Participant 1 Image

Group	Value	95% CI
Image Quality of the Digital Image Enhancement (DIE) Group	9
Image Quality of the Control Group	NA

Participant 2 Image

Group	Value	95% CI
Image Quality of the Digital Image Enhancement (DIE) Group	NA
Image Quality of the Control Group	8

Participant 3 Image

Group	Value	95% CI
Image Quality of the Digital Image Enhancement (DIE) Group	8
Image Quality of the Control Group	NA

Participant 4 Image

Group	Value	95% CI
Image Quality of the Digital Image Enhancement (DIE) Group	NA
Image Quality of the Control Group	7

Participant 5 Image

Group	Value	95% CI
Image Quality of the Digital Image Enhancement (DIE) Group	NA
Image Quality of the Control Group	9

Operative Time Secondary · intraoperatively

Participant 1

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	51
Control Group	NA

Participant 2

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	103

Participant 3

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	79
Control Group	NA

Participant 4

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	80

Participant 5

Group	Value	95% CI
Digital Image Enhancement (DIE) Group	NA
Control Group	125

Sponsor's own description

The purpose of this study is to evaluate the effectiveness of a novel digital image enhancement (DIE) technology in reducing the radiation exposure to both the patient and surgical staff during standard intramedullary nail placement for treatment of hip fractures. Secondarily, to evaluate whether the image quality and reproducibility of desired images can be improved with use of the DIE technology. Finally, to evaluate whether DIE technology reduces total operative time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Radiation Exposure

Currently open trials in the same condition.

NCT06875583 — The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial · NA · recruiting
NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
NCT06384105 — Study of the Patient Radiation Dose During Five Endourological Procedures · NA · recruiting
NCT06360627 — Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT · NA · recruiting
NCT05203250 — Longitudinal Registry Including Patients Treated With Heavy Particles · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02856828 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 15 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02856828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing